Table 4. Univariate and multivariate analysis related to OS and PFS in 60 mCRC treated with anti-EGFR mAb cetuximab.

Variables					Overall Survival (OS)
			Univariate						Multivariate
	HR		95% CI		P-value			HR	95% CI		P-value
Vascular Invasion	0.201		0.048–0.834		0.027			0.204	0.049–0.852		0.029
BTC†	3.228		1.337–7.791		0.009			4.463	1.235–16.133		0.023
Epigen (2+)	4.867		1.610–14.707		0.005			11.533	2.092–63.569		0.005
TGFα (>20%)	0.368		0.153–0.887		0.026			0.073	0.009–0.612		0.016

						Progression-free Survival (PFS)
				Univariate						Multivariate
		HR		95% CI		P-value	HR			95% CI		P-value
Tumour Stage		0.442		0.202–0.966		0.041	0.351			0.146–0.844		0.019
wtEGFR (> 5%)		2.752		1.519–4.989		0.001	2.829			1.316–6.079		0.008
Amphiregulin (2+)		4.554		1.301–15.936		0.018	-			-		NS
wtEGFR/1 ligand		2.673		1.480–4.826		0.001	2.717			1.274–5.792		0.010
wtEGFR/2 ligands		2.141		1.187–3.862		0.011	2.306			1.093–4.862		0.028
wtEGFR/Epigen*		2.063		1.111–3.831		0.022	2.450			1.119–5.364		0.025
wtEGFR/BTC**		4.136		1.701–10.056		0.002	3.814			1.315–11.060		0.014

Abbreviations: HR, hazard ratio; CI, confidence interval; †, cut-off value > 50% used for OS and PFS; *, cut-off value of > 5% used; **, cut-off value of > 5% (wtEGFR) and > 50% (BTC); NS, Not significant

P-value of ≤ 0.05 was considered significant